Immunocore (NASDAQ:IMCR) CEO Bahija Jallal Sells 11,474 Shares of Stock

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) CEO Bahija Jallal sold 11,474 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total value of $371,183.90. Following the completion of the transaction, the chief executive officer directly owned 12,343 shares in the company, valued at $399,296.05. This trade represents a 48.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Immunocore Stock Performance

Shares of IMCR traded down $0.78 during mid-day trading on Friday, hitting $32.40. 87,179 shares of the company traded hands, compared to its average volume of 453,159. Immunocore Holdings PLC Sponsored ADR has a 1 year low of $23.15 and a 1 year high of $40.71. The company has a debt-to-equity ratio of 0.99, a quick ratio of 5.97 and a current ratio of 6.00. The stock has a 50-day moving average price of $33.89 and a two-hundred day moving average price of $34.30. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -56.83 and a beta of 0.78.

Analysts Set New Price Targets

IMCR has been the subject of a number of recent research reports. UBS Group set a $55.00 price objective on shares of Immunocore and gave the company a “buy” rating in a research report on Wednesday, January 7th. Wells Fargo & Company began coverage on shares of Immunocore in a research report on Friday, October 31st. They set an “overweight” rating and a $60.00 price objective on the stock. Mizuho set a $38.00 target price on Immunocore in a research report on Thursday. Zacks Research raised shares of Immunocore from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 7th. Finally, Morgan Stanley raised their price objective on Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a research note on Monday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $60.90.

Institutional Trading of Immunocore

A number of hedge funds have recently added to or reduced their stakes in IMCR. XTX Topco Ltd purchased a new stake in shares of Immunocore in the 4th quarter worth approximately $763,000. Voloridge Investment Management LLC bought a new position in Immunocore in the fourth quarter worth approximately $978,000. Vestal Point Capital LP bought a new position in Immunocore in the fourth quarter worth approximately $20,305,000. Virtus Investment Advisers LLC lifted its stake in shares of Immunocore by 48.9% during the 4th quarter. Virtus Investment Advisers LLC now owns 18,569 shares of the company’s stock worth $645,000 after purchasing an additional 6,097 shares during the last quarter. Finally, Susquehanna Portfolio Strategies LLC lifted its position in shares of Immunocore by 162.0% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 27,607 shares of the company’s stock valued at $958,000 after buying an additional 17,069 shares during the last quarter. 84.50% of the stock is owned by hedge funds and other institutional investors.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.